𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination

✍ Scribed by Aida Kerkmann-Tucek; G.-André Banat; Björn Cochlovius; Margot Zöller

Publisher
John Wiley and Sons
Year
1998
Tongue
French
Weight
307 KB
Volume
77
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Vaccination with tumour cells genetically modified to support induction of an immune response either by production of cytokines or expression of co-stimulatory molecules provides a promising therapeutic approach. We have evaluated the efficiency of tumour vaccination using RENCA cells, a renal cell carcinoma of the BALB/c strain, which were stably transfected with MHC class II, B7.1 or both. Tumour growth after vaccination with MHC class II and/or B7.1 transfected RENCA cells was extremely variable, with protection close to 100% after vaccination with some clones and no effect of vaccination with others. To unravel the underlying mechanism, untransfected RENCA cells were cloned, and individual clones were tested for immunogenicity; that cloned RENCA cells varied considerably in immunogenicity. Whereas all clones displayed comparable growth rates in nude mice, some grew very slowly in immunocompetent syngenetic hosts. Vaccination with rapidly growing clones was ineffective and, importantly, this feature remained unaltered by vaccination with MHC class II and/or B7.1 transfected clones. Instead, 8 of 10 mice rejected the parental line after immunisation with a pool of MHC class II and B7.1 transfected clones. Finally, by cloning RENCA cells, we obtained one highly immunogenic clone (P2). Vaccination with this clone led to an individual-specific response, which indicates that during the cloning procedure a new strongly immunogenic entity must have arisen. Taken together, our results indicate that vaccination with MHC II and/or B7.1 transfected tumour cells induces an efficient immune response, but only if the tumour is weakly immunogenic. Since tumours may be composed of clones displaying different antigenicities, it is mandatory to use bulk cell populations for transfection and vaccination.

📜 SIMILAR VOLUMES

Vaccination with ant-idiotype antibodies
Vaccination with ant-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity
✍ 12 Hirotsugu Uemura; Antonius J. M. C. Beniers; Eigoro Okajima; Frans M. J. Debr 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 830 KB

We have previously isolated and characterized 6 different internal image mouse monoclonal anti-idiotype antibodies (Ab2) directed against the paratope of mouse monoclonal antibody G250 (MAbG250, Abl), which specifically reacts with human renal cell carcinoma (RCC). These Ab2s (NUH3 I, 44.5 I, 7 I, 8

Induction of tumor-cell lysis by bi-spec
Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and cd3 antigen
✍ J. Van Duk; S. O. Warnaar; J. D. H. Van Eendenburg; M. Thienpont; E. Braakman; J 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 644 KB

## Bi -specific monoclonal antibodies (MAbs) were developed by somatic hybridization of 2 mouse hybridomas, one producing MAb against the G250 renal-cell carcinoma (RCC)-associated antigen and the other against the T-cell antigen CD3 (OKT3). The dual specificity of the hybrid MAb produced by these

Cytotoxic T lymphocytes recognize tumor
Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors
✍ Monica Rodolfo; Chiara Castelli; Cinzia Bassi; Paola Accornero; Marialuisa Sensi 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 889 KB

To see whether different antigens expressed by the same tumor are recognized by distinct T-cell receptors (TCR), we used cytotoxic T-lymphocyte (CTL) lines known to lyse in vitro the syngeneic BALB/c adenocarcinoma C-26. Four of these CD3+ CD8+ lines showed 4 different patterns of lysis on a panel o

Generation of cytotoxic T-cell responses
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
✍ Elke Jäeger; Helga Bernhard; Pedro Romero; Mark Ringhoffer; Michael Arand; Julia 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 954 KB

Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identified in human melanomas and normal cultured melanocytes as targets for MHC-restricted

Elimination of regulatory T cells is ess
Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model
✍ Oliver M. Grauer; Roger P.M. Sutmuller; Wendy van Maren; Joannes F.M. Jacobs; Er 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 230 KB 👁 1 views

## Abstract Both melanoma and glioma cells are of neuroectodermal origin and share common tumor associated antigens. In this article, we report that the melanocyte differentiation antigen TRP2 (tyrosinase‐related protein 2) is not predominately involved in the tumor rejection of a syngeneic murine

Prognostic relevance of the mTOR pathway
Prognostic relevance of the mTOR pathway in renal cell carcinoma : Implications for molecular patient selection for targeted therapy
✍ Allan J. Pantuck; David B. Seligson; Tobias Klatte; Hong Yu; John T. Leppert; La 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 980 KB

## Abstract ## BACKGROUND. The mammalian target of rapamycin (mTOR) pathway is up‐regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway